CoChat

Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2

Open access
Mulvihill, Erin E. · 2018 · Current Opinion in Lipidology

The DOI matches its Crossref record; 89 of the 93 references it cites were found in a registry or an index.

Abstract

Purpose of review: The intestine is highly efficient at absorbing and packaging dietary lipids onto the structural protein apoB48 for distribution throughout the body. Here, we summarize recent advances into understanding the physiological and pharmacological actions of the proglucagon-derived peptides: glucagon like peptide 1 (GLP-1) and glucagon like peptide 2 (GLP-2) on intestinal lipoprotein secretion. Recent findings: Several recent studies have elucidated mechanisms underlying the paradoxical effects of GLP-1 and GLP-2 on intestinal production of triglyceride-rich lipoproteins (TRLs). Both gut-derived peptides are secreted on an equimolar basis in response to the same nutrient stimulus. Despite neither receptor demonstrating clear localization to enterocytes, a single injection of a GLP-1R agonist rapidly decreases delivery of intestinally packaged fatty acids into the plasma, while conversely GLP-2 receptor (GLP-2R) activation acutely increases TRL concentrations in plasma. Summary: The regulation of TRL secretion is dependent on the coordination of many processes: fatty acid availability uptake, assembly onto the apoB48 polypeptide backbone, secretion and reuptake, which the hormonal, neural, inflammatory and metabolic milieu can all strongly influence. Understanding of how GLP-1 and GLP-2 receptor agonists control TRL production has clinical importance given that GLP1R agonists were recently demonstrated not only to provide glycemic control but also to prevent major adverse cardiovascular events in patients with T2DM and the success of GLP-2R agonists in treating short bowel disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/mol.0000000000000495

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Figures

Box 1 no caption available
Box 1 no caption availableCC BY-NC-ND · PubMed Central
FIGURE 1 (a) GLP-1R mediated decrease in the production rate of intestinally derived, triglyceride-rich lipoproteins is independent of increased insulin secretion and reduced glucagon secretion, reduced gastric emptying and weight loss or anorectic effects. (b) Potential mechanisms in need of validation for GLP-1R mediated reductions in TRL-TG and TRL- apoB48 synthesis and secretion including signalling through the peripheral gut:brain axis, lymph flow and the central nervous system.
FIGURE 1 (a) GLP-1R mediated decrease in the production rate of intestinally derived, triglyceride-rich lipoproteins is independent of increased insulin secretion and reduced glucagon secretion, reduced gastric emptying and weight loss or anorectic effects. (b) Potential mechanisms in need of validation for GLP-1R mediated reductions in TRL-TG and TRL- apoB48 synthesis and secretion including signalling through the peripheral gut:brain axis, lymph flow and the central nervous system.CC BY-NC-ND · PubMed Central
FIGURE 2 Emerging evidence suggests that GLP-2R activation increases the secretion of preformed chylomicron particles. Potential mechanisms in need of validation for GLP-2R mediated increases in TRL-TG and TRL-apoB48 synthesis and secretion including increased blood flow and secondary mediators.
FIGURE 2 Emerging evidence suggests that GLP-2R activation increases the secretion of preformed chylomicron particles. Potential mechanisms in need of validation for GLP-2R mediated increases in TRL-TG and TRL-apoB48 synthesis and secretion including increased blood flow and secondary mediators.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 89 references

Cited by

See all 32

Metadata

Authors
Mulvihill, E. E.
Affiliations
University of Ottawa (CA)
Corresponding author
Mulvihill, Erin E.
Venue
Current Opinion in Lipidology
Published
2018-04
Volume
29
Issue
2
Pages
95-103
ISSN
  • 0957-9672 (ISSN-L)
  • 1473-6535
OpenAlex
W2792260658
Cited by
29
References
93
Citations by year
2026: 2 · 2025: 2 · 2024: 4 · 2023: 1 · 2022: 6 · 2021: 6 · 2020: 5 · 2019: 3
FWCI
0.65
Type
journal article
Language
en
Open access
Locations
  • Current Opinion in Lipidology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
glucagon-like peptide-1, glucagon-like peptide-2, proglucagon-derived peptides, intestinal lipid metabolism, lipoprotein secretion, triglyceride-rich lipoproteins, apoB-48, GLP-1 receptor agonists, short bowel syndrome, type 2 diabetes, fatty acid uptake, enterocytes
MeSH terms
Animals, Humans, Intestinal Mucosa, Lipoproteins, Glucagon-Like Peptide 1, Glucagon-Like Peptide 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2. https://app.cochat.ai/papers/10.1097/mol.0000000000000495
The paper
Mulvihill, E. E. (2018). Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2. Current Opinion in Lipidology. https://doi.org/10.1097/mol.0000000000000495

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.